Gut Microbiome Linked to Colorectal Cancer Recurrence Risk | HemOnc Today

The gut microbiome—the complex community of bacteria and other microorganisms living in our digestive tracts—may play a significant role in whether colorectal cancer returns after initial treatment. A new analysis, published March 4, 2026, in JCO Oncology Advances, suggests specific bacterial compositions are linked to increased risk of recurrence, potentially opening avenues for new preventative strategies.

Microbial Signatures and Recurrence Risk

Researchers analyzed data from nearly 300 patients who underwent surgical resection for stage I to III colorectal cancer. They collected fecal samples before surgery to assess the composition of each patient’s gut microbiome. After a median follow-up of 56 months, approximately 21% of participants experienced cancer recurrence. The study revealed distinct microbial differences between those who experienced recurrence and those who remained cancer-free.

While overall bacterial diversity didn’t differ significantly between the two groups, the types of bacteria present did. Specifically, higher levels of Porphyromonas were nearly three times as likely to be associated with overall cancer recurrence (HR = 2.8; 95% CI, 1.54-5.1). Other bacteria linked to specific recurrence patterns included Acidaminococcus, Alloprevotella, Butyrivibrio, Ruminococcaceae CAG-352 and Lachnospiraceae UCG-003, which were associated with locoregional recurrence; Megamonas, linked to distant recurrence; and Anaeroplasma, too associated with overall recurrence.

“Not only does the tumor itself matter, but also the environment in which it develops and exists,” explained Anne E. Petersen, MD, PhD candidate in pediatric surgery at Amsterdam University Medical Centers, in a statement to Healio. Petersen and colleagues conducted a prospective investigation to explore the potential link between the gut microbiome and colorectal cancer recurrence.

Understanding the Gut-Cancer Connection

Colorectal cancer is the third most commonly diagnosed cancer in the United States, with approximately 153,020 new cases expected in 2024, according to the American Cancer Society. While surgery is often curative for early-stage disease, recurrence remains a significant concern. Current prediction models rely on factors like tumor stage and genetic markers, but these don’t always accurately predict who will experience recurrence.

The gut microbiome has emerged as a critical player in cancer development, and progression. It influences immune function, inflammation, and even the metabolism of cancer drugs. The idea that it could also impact recurrence is a relatively new area of investigation. Petersen and colleagues hypothesized that the microbiome’s composition could provide additional insights into a patient’s risk.

“The microbiome is a fascinating and complex system,” Petersen said. “It is well-known that the gut microbiome is involved in development of colorectal cancer, but that this is also the case with recurrence is a new finding.”

Study Details and Limitations

The study involved 294 patients with stage I-III colorectal cancer who underwent surgical resection. Researchers analyzed fecal samples collected *before* surgery to minimize the influence of treatment on the microbiome. They used microbial abundance and diversity as the primary endpoint, correlating these factors with the occurrence of locoregional, distant, or overall recurrence.

While the findings are promising, the researchers acknowledge several limitations. The study only collected microbiome samples at a single time point, before surgery. This means they couldn’t assess how the microbiome changed over time or how treatment might have altered its composition. The study identified associations between specific bacteria and recurrence, but it couldn’t prove that these bacteria *caused* recurrence. It’s possible that the microbiome changes were a consequence of the tumor itself, rather than a driver of recurrence.

What Does This Mean for Patients?

These findings do not mean patients should immediately seek microbiome testing or produce changes to their diet or lifestyle. Still, they do suggest that the gut microbiome could be a valuable target for future research and potential interventions.

“We do not yet recognize whether the microbiome is simply a consequence of a more aggressive tumor, thereby reflecting a higher risk of recurrence, or whether the microbiome itself actively contributes to recurrence,” Petersen explained. “Understanding this distinction will be crucial for translating these findings into clinical practice.”

Future Directions and Clinical Implications

The research team plans to validate these findings in a larger, independent cohort of patients. They also intend to employ more advanced sequencing techniques, known as shotgun sequencing, to identify the specific bacterial species involved in recurrence. This could lead to a more precise understanding of the mechanisms by which the microbiome influences cancer progression.

If these findings are confirmed, profiling the preoperative microbiome—specifically, detecting the abundance of Porphyromonas—could potentially contribute to risk stratification, helping clinicians identify patients who are at higher risk of recurrence and may benefit from more intensive surveillance or adjuvant therapies. However, Petersen cautioned that targeted therapies based on microbiome profiling are still speculative at this stage.

The National Cancer Institute provides comprehensive information on colorectal cancer, including risk factors, screening guidelines, and treatment options. Patients with concerns about colorectal cancer should consult with a qualified healthcare professional.

Ongoing research will focus on determining whether manipulating the gut microbiome—through dietary changes, probiotics, or fecal microbiota transplantation—could reduce the risk of colorectal cancer recurrence.